Business
Control-IQ Technology Continues to Demonstrate Positive and Sustained Real-World Benefits Across Diverse Cohorts of People with Diabetes
NEW ORLEANS--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced positive
About this update from Tandem Diabetes Care, Inc.
[{"type":"text","content":" NEW ORLEANS--(BUSINESS WIRE)--\nTandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced positive real-world data demonstrating immediate and sustained benefits in a diverse cohort of people using the t:slim X2™ insulin pump with Control-IQ® technology. The data was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans.\n\n“Our Control-IQ technology continues to be a great equalizer for people with insulin-intensive diabetes, as we consistently see positive clinical and quality-of-life improvement with its use, regardless of age, ethnicity, or prior therapy,” said Jordan Pinsker, MD, Vice President and Medical Director for Tandem Diabetes Care. “This evidence increases our motivation to bring new advances in technology to benefit people living with diabetes worldwide.”\n\nData presented at the conference comes from the Control-IQ Observational (CLIO) study, an ongoing real-world, longitudinal study of people using the t:slim X2 insulin pump with Control-IQ technology.\n\nSummaries of ADA Scientific Sessions Presentations\n\nPsychosocial Benefits of Using Control-IQ Technology: Long-term Outcomes from a Multi-Ethnic Adult Cohort with Type 1 Diabetes1\n\nNamed as an ADA Presidents' Select Abstract Presentation, this analysis features patient-reported outcomes from an ethnically diverse cohort of 1,306 adults. Results demonstrated significant improvements in diabetes-specific quality of life, satisfaction with insulin delivery device, and reduction in diabetes-related burden over 12 months with Control-IQ technology. Psychosocial benefits of Control-IQ technology were experienced by all ethnic cohorts. Significantly improved quality of sleep was also noted for all participants using the system.\n\nEvaluation of Long-Term Glycemic Outcomes by Ethnicity in Adults with Type 1 Diabetes Using Control-IQ Technology2\n\nThis study assessed relationships between ethnicity, baseline HbA1c, Glucose Management Indicator (GMI), and sensor Time in Range (TIR) (70-180mg/dL) for 1,045 adult CLIO participants (Asian, Black/African American, White, and Hispanic/Latino/Spanish). GMI at study end reflected glycemic improvements for all participants, with Black/African American participants showing a clinically relevant 0.7% overall reduction.\n\nLong-term Gl...